Published in Nat Biotechnol on January 01, 2002
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 3.11
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
CARs on track in the clinic. Mol Ther (2011) 2.86
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Designing customized cell signalling circuits. Nat Rev Mol Cell Biol (2010) 2.64
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood (2010) 2.59
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature (2017) 2.43
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res (2013) 1.85
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell (2015) 1.74
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 1.71
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res (2014) 1.69
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 1.65
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Safer CARS. Mol Ther (2010) 1.46
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
20 years of Nature Biotechnology biomedical research. Nat Biotechnol (2016) 1.42
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol (2009) 1.40
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 1.39
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 1.37
Overview of prostate-specific membrane antigen. Rev Urol (2004) 1.34
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther (2013) 1.33
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev (2014) 1.33
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J (2012) 1.26
Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther (2013) 1.21
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol (2011) 1.17
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res (2015) 1.17
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res (2011) 1.15
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A (2005) 1.14
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res (2014) 1.08
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One (2013) 1.08
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.06
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Genetic engineering of T cells for adoptive immunotherapy. Immunol Res (2008) 1.05
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology (2015) 1.04
Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol (2011) 1.04
Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One (2010) 1.03
Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res (2008) 1.03
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res (2014) 1.03
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res (2010) 1.02
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther (2013) 1.00
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev (2016) 0.95
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem (2010) 0.95
Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A (2014) 0.94
Nature Biotechnology's academic spinouts of 2013. Nat Biotechnol (2014) 0.93
Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy (2010) 0.93
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
Engineering CAR-T cells: Design concepts. Trends Immunol (2015) 0.93
Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol (2011) 0.92
Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res (2014) 0.91
Cellular immunotherapy for high-grade glioma. Immunotherapy (2011) 0.91
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood (2014) 0.90
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res (2013) 0.89
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica (2012) 0.88
CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. Clin Exp Immunol (2006) 0.88
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Immunotherapy and tumor microenvironment. Cancer Lett (2015) 0.88
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol (2009) 13.16
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 5.66
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol (2009) 5.44
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 3.11
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci U S A (2009) 2.86
CARs on track in the clinic. Mol Ther (2011) 2.86
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A (2010) 2.67
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol (2010) 2.43
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell (2011) 2.33
Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer (2003) 2.08
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med (2009) 1.98
T-cell therapy at the threshold. Nat Biotechnol (2012) 1.91
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood (2002) 1.89
Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood (2012) 1.87
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med (2013) 1.76
A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells (2010) 1.73
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther (2007) 1.62
Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol (2005) 1.54
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol (2012) 1.50
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res (2011) 1.48
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res (2003) 1.43
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 1.39
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med (2008) 1.35
A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res (2011) 1.33
Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood (2002) 1.29
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood (2010) 1.29
The ABCs of artificial antigen presentation. Nat Biotechnol (2004) 1.29
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther (2003) 1.29
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol (2005) 1.28
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 1.25
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res (2012) 1.25
Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A (2005) 1.24
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol (2008) 1.24
CAR therapy: the CD19 paradigm. J Clin Invest (2015) 1.20
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One (2013) 1.19
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. J Clin Invest (2008) 1.16
Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol (2006) 1.16
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res (2013) 1.16
In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res (2007) 1.15
The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther (2007) 1.13
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother (2011) 1.12
Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene (2002) 1.12
Hematopoietic stem cell engineering at a crossroads. Blood (2011) 1.10
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
The potential of stem cells as an in vitro source of red blood cells for transfusion. Cell Stem Cell (2012) 1.06
Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res (2002) 1.03
Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol (2006) 1.03
Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. Biol Blood Marrow Transplant (2012) 1.02
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res (2010) 1.02
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood (2010) 1.01
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate (2009) 1.00
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med (2010) 1.00
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 0.99
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med (2010) 0.99
Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nat Protoc (2011) 0.99
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood (2014) 0.97
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood (2003) 0.97
High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol (2013) 0.97
A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. J Immunol (2009) 0.97
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest (2013) 0.96
Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals. J Immunol (2004) 0.95